Karnataka rain fury: Photos of flooded streets, uprooted trees
Cannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfit
Ranbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A Kiss
Oscars 2022: Every Academy Award Winner
Shane Warne (1969-2022): Australian cricket legend's life in pictures
Photos: What Russia's invasion of Ukraine looks like on the ground
Lata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'
PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Wedding pics: Mouni Roy marries Suraj Nambiar in South Indian ceremony
73rd Republic Day Parade 2022 - In Pictures
World no. 1 Serbian tennis great Novak Djokovic was named Laureus World Sportsman of the Y
- Asian Games medallist Jyothi Yarraji to train in Spain ahead of Paris Olympics
- Lione Messi said Retirement not on my mind
- Indian Wells: Alcaraz, Swiatek win titles
- African footballer chased and thrashed away in Kerala; reports
- Hockey India announce core probable group for men's national camp in Bhubaneswar
Covid-19: DCGI approves phase II-III clinical trials of Covaxin on children aged 2 to 18 years Last Updated : 13 May 2021 01:04:29 PM IST 
The Drugs Controller General of India (DCGI) has accorded permission to conduct the Phase II-III clinical trial of Covaxin (Covid vaccine) in the age group of two to 18-years-old to its manufacturer Bharat Biotech Ltd, Union Health Ministry said on Thursday.
"The trial will be conducted in 525 healthy volunteers," said the Ministry.
In the trial, the Ministry said, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.
After careful examination, the DCGI accepted the recommendation of Subject Expert Committee (SEC). The national drug regulator of the country on Wednesday gave the approval to conduct the clinical trial in the age group of youngest age group till now paving way for them to be saved from the deadly pandemic outbreak.
Hyderabad-based Bharat Biotech International Ltd (BBIL) had proposed to carry out a Phase II-III clinical trial of Covaxin in the age group of two to 18 years.
As rapid regulatory response, the proposal was deliberated in Subject Expert Committee (SEC) (Covid-19) on May 11 this year.
The committee after detailed deliberation recommended for grant of permission to conduct proposed Phase II-III clinical trial to certain conditions.
IANS New Delhi For Latest Updates Please-
Join us on
Follow us on
What binds the two most talked about nations - India and Pakistan together? What makes the
Actor Emraan Hashmi is set to don a never-seen-before avatar of the freedom fighter -- Ram
LG Electronics Inc said on Wednesday that it will introduce new C with its artificial inte
172.31.16.186
